

Andrea Cippitelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1509690/publications.pdf>

Version: 2024-02-01

54
papers

3,317
citations

159358

30
h-index

155451

55
g-index

55
all docs

55
docs citations

55
times ranked

3015
citing authors

#	ARTICLE	IF	CITATIONS
1	PPL-138 (BU10038): A bifunctional NOP/mu partial agonist that reduces cocaine self-administration in rats. <i>Neuropharmacology</i> , 2022, 211, 109045.	2.0	6
2	PPL-103: A mixed opioid partial agonist with desirable anti-cocaine properties. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 119, 110599.	2.5	2
3	The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies. <i>CNS Drugs</i> , 2021, 35, 591-607.	2.7	11
4	Potent and selective NOP receptor activation reduces cocaine self-administration in rats by lowering hedonic set point. <i>Addiction Biology</i> , 2020, 25, e12844.	1.4	10
5	NOP receptor agonist attenuates nitroglycerin-induced migraine-like symptoms in mice. <i>Neuropharmacology</i> , 2020, 170, 108029.	2.0	16
6	NOP Receptor Antagonists Decrease Alcohol Drinking in the Dark in C57BL/6J Mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 2167-2178.	1.4	18
7	NOP-Related Mechanisms in Pain and Analgesia. <i>Handbook of Experimental Pharmacology</i> , 2019, 254, 165-186.	0.9	18
8	Analysis of the distribution of spinal NOP receptors in a chronic pain model using NOP-eGFP knock-in mice. <i>British Journal of Pharmacology</i> , 2018, 175, 2662-2675.	2.7	20
9	Differential regulation of alcohol taking and seeking by antagonism at $\hat{1}\pm 4\hat{1}^2$ and $\hat{1}\pm 3\hat{1}^2$ nAChRs. <i>Psychopharmacology</i> , 2018, 235, 1745-1757.	1.5	8
10	Influence of neuropathic pain on nicotinic acetylcholine receptor plasticity and behavioral responses to nicotine in rats. <i>Pain</i> , 2018, 159, 2179-2191.	2.0	15
11	PPAR $\hat{1}\pm$ /CB1 receptor dual ligands as a novel therapy for alcohol use disorder: Evaluation of a novel oleic acid conjugate in preclinical rat models. <i>Biochemical Pharmacology</i> , 2018, 157, 235-243.	2.0	9
12	Protection against alcohol-induced neuronal and cognitive damage by the PPAR $\hat{1}^3$ receptor agonist pioglitazone. <i>Brain, Behavior, and Immunity</i> , 2017, 64, 320-329.	2.0	37
13	Highly Selective and Potent $\hat{1}\pm 4\hat{1}^2$ nAChR Antagonist Inhibits Nicotine Self-Administration and Reinstatement in Rats. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 10092-10104.	2.9	9
14	In Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential. <i>Frontiers in Psychiatry</i> , 2017, 8, 52.	1.3	14
15	Role of the satiety factor oleoylethanolamide in alcoholism. <i>Addiction Biology</i> , 2016, 21, 859-872.	1.4	58
16	A key role for the N/OFQ-NOP receptor system in modulating nicotine taking in a model of nicotine and alcohol co-administration. <i>Scientific Reports</i> , 2016, 6, 26594.	1.6	29
17	Neurokinin 1 receptor blockade in the medial amygdala attenuates alcohol drinking in rats with innate anxiety but not in Wistar rats. <i>British Journal of Pharmacology</i> , 2015, 172, 5136-5146.	2.7	18
18	PPAR $\hat{1}^3$ Activation Attenuates Opioid Consumption and Modulates Mesolimbic Dopamine Transmission. <i>Neuropsychopharmacology</i> , 2015, 40, 927-937.	2.8	67

#	ARTICLE	IF	CITATIONS
19	<scp>AT</scp>â€1001: a highâ€affinity Î±3Î²4 <scp>nAChR</scp> ligand with novel nicotineâ€suppressive pharmacology. <i>British Journal of Pharmacology</i> , 2015, 172, 1834-1845.	2.7	31
20	Pharmacological stress is required for the anti-alcohol effect of the Î±3Î²4* nAChR partial agonist AT-1001. <i>Neuropharmacology</i> , 2015, 93, 229-236.	2.0	16
21	Varenicline decreases nicotine but not alcohol self-administration in genetically selected Marchigian Sardinian alcohol-preferring (msP) rats. <i>Drug and Alcohol Dependence</i> , 2015, 156, 126-132.	1.6	17
22	Knock-In Mice with NOP-eGFP Receptors Identify Receptor Cellular and Regional Localization. <i>Journal of Neuroscience</i> , 2015, 35, 11682-11693.	1.7	56
23	Polymorphism in the corticotropin-releasing factor receptor 1 (CRF1-R) gene plays a role in shaping the high anxious phenotype of Marchigian Sardinian alcohol-preferring (msP) rats. <i>Psychopharmacology</i> , 2015, 232, 1083-1093.	1.5	25
24	Binge-like ethanol consumption increases corticosterone levels and neurodegeneration whereas occupancy of type II glucocorticoid receptors with mifepristone is neuroprotective. <i>Addiction Biology</i> , 2014, 19, 27-36.	1.4	33
25	Chronic THC during adolescence increases the vulnerability to stress-induced relapse to heroin seeking in adult rats. <i>European Neuropsychopharmacology</i> , 2014, 24, 1037-1045.	0.3	59
26	Pregabalin reduces cocaine self-administration and relapse to cocaine seeking in the rat. <i>Addiction Biology</i> , 2013, 18, 644-653.	1.4	32
27	Activation of <scp>PPAR</scp>Î³ by Pioglitazone Potentiates the Effects of Naltrexone on Alcohol Drinking and Relapse in ms<scp>P</scp> Rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 1351-1360.	1.4	77
28	Role of a Genetic Polymorphism in the Corticotropin-Releasing Factor Receptor 1 Gene in Alcohol Drinking and Seeking Behaviors of Marchigian Sardinian Alcohol-Preferring Rats. <i>Frontiers in Psychiatry</i> , 2013, 4, 23.	1.3	42
29	Pharmacological blockade of corticotropin-releasing hormone receptor 1 (CRH1R) reduces voluntary consumption of high alcohol concentrations in non-dependent Wistar rats. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 100, 522-529.	1.3	76
30	Melanin-concentrating hormone receptor 1 (MCH1-R) antagonism: Reduced appetite for calories and suppression of addictive-like behaviors. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 102, 400-406.	1.3	30
31	Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat. <i>Psychopharmacology</i> , 2012, 220, 87-96.	1.5	29
32	Activation of Nuclear PPARÎ³ Receptors by the Antidiabetic Agent Pioglitazone Suppresses Alcohol Drinking and Relapse to Alcohol Seeking. <i>Biological Psychiatry</i> , 2011, 69, 642-649.	0.7	131
33	Role of Feeding-Related Pathways in Alcohol Dependence: A Focus on Sweet Preference, NPY, and Ghrelin. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 194-202.	1.4	66
34	Activation of Brain NOP Receptors Attenuates Acute and Protracted Alcohol Withdrawal Symptoms in the Rat. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 747-755.	1.4	63
35	The novel, selective, brain-penetrant neuropeptide Y Y2 receptor antagonist, JNJ-31020028, tested in animal models of alcohol consumption, relapse, and anxiety. <i>Alcohol</i> , 2011, 45, 567-576.	0.8	42
36	Endocannabinoid Regulation of Acute and Protracted Nicotine Withdrawal: Effect of FAAH Inhibition. <i>PLoS ONE</i> , 2011, 6, e28142.	1.1	70

#	ARTICLE	IF	CITATIONS
37	Neuropeptide Y (NPY) suppresses yohimbine-induced reinstatement of alcohol seeking. <i>Psychopharmacology</i> , 2010, 208, 417-426.	1.5	71
38	Suppression of alcohol self-administration and reinstatement of alcohol seeking by melanin-concentrating hormone receptor 1 (MCH1-R) antagonism in Wistar rats. <i>Psychopharmacology</i> , 2010, 211, 367-375.	1.5	51
39	Reversibility of object recognition but not spatial memory impairment following binge-like alcohol exposure in rats. <i>Neurobiology of Learning and Memory</i> , 2010, 94, 538-546.	1.0	39
40	Alcohol-Induced Neurodegeneration, Suppression of Transforming Growth Factor- β 2, and Cognitive Impairment in Rats: Prevention by Group II Metabotropic Glutamate Receptor Activation. <i>Biological Psychiatry</i> , 2010, 67, 823-830.	0.7	56
41	Stress-related neuropeptides and alcoholism: CRH, NPY, and beyond. <i>Alcohol</i> , 2009, 43, 491-498.	0.8	52
42	Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. <i>Psychopharmacology</i> , 2008, 198, 449-460.	1.5	103
43	Dysregulation of Nociceptin/Orphanin FQ Activity in the Amygdala Is Linked to Excessive Alcohol Drinking in the Rat. <i>Biological Psychiatry</i> , 2008, 64, 211-218.	0.7	115
44	3-(4-Chloro-2-Morpholin-4-yl-Thiazol-5-yl)-8-(1-Ethylpropyl)-2,6-Dimethyl-Imidazo[1,2-b]Pyridazine: A Novel Brain-Penetrant, Orally Available Corticotropin-Releasing Factor Receptor 1 Antagonist with Efficacy in Animal Models of Alcoholism. <i>Journal of Neuroscience</i> , 2007, 27, 2718-2726.	1.7	232
45	Region-specific down-regulation of Crhr1 gene expression in alcohol-preferring msP rats following ad lib access to alcohol. <i>Addiction Biology</i> , 2007, 12, 30-34.	1.4	81
46	The anandamide transport inhibitor <i>AM404</i> reduces ethanol self-administration. <i>European Journal of Neuroscience</i> , 2007, 26, 476-486.	1.2	64
47	Activation of the Nociceptin/Orphanin FQ system is unable to reverse CRF2 receptor mediated anorexia in the rat. <i>Peptides</i> , 2006, 27, 3284-3291.	1.2	6
48	Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole "LH 21". <i>Neuropharmacology</i> , 2006, 51, 358-366.	2.0	116
49	Absence of quasi-morphine withdrawal syndrome in adenosine A2A receptor knockout mice. <i>Psychopharmacology</i> , 2006, 185, 160-168.	1.5	20
50	Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. <i>European Journal of Neuroscience</i> , 2005, 21, 2243-2251.	1.2	135
51	THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY. <i>Alcohol and Alcoholism</i> , 2005, 40, 2-14.	0.9	305
52	Nociceptin/orphanin FQ acts as a functional antagonist of corticotropin-releasing factor to inhibit its anorectic effect. <i>Physiology and Behavior</i> , 2004, 82, 63-68.	1.0	67
53	Hypericum perforatum CO2 Extract and Opioid Receptor Antagonists Act Synergistically to Reduce Ethanol Intake in Alcohol-Preferring Rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2003, 27, 1554-1562.	1.4	25
54	A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding. <i>Journal of Neuroscience</i> , 2002, 22, 9612-9617.	1.7	492